opc,

I don't think the T2's were ever priced into the model going into CRL #2 since it hadn't been studied in them. Just because a doc wants to use a drug off-label does not mean insurance will cover it. And risk for its use then falls on the doc. So you couldn't officially factor in too many T2's into the equation.

But that is what really drew me into MNKD. Everyone knew they were going for the T1 label and priced accordingly. What I knew is that it wouldn't be too hard to get the T2 label, and that hadn't been priced in.